Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Uller (Lund, Sweden). Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation. Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

Member's Comments

No comment yet.

Related content which might interest you: Translating mechanisms to new drugs for COPD exacerbations Source: Annual Congress 2009 - LANCET/ERS symposium: “Evolving dimensions of COPD” Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 Airway inflammation in asthma: current and future targets and therapies Source: Breathe 2010; 6: 245-252 Year: 2010 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations Source: Eur Respir J, 50 (4) 1602434; 10.1183/13993003.02434-2016 Year: 2017 New and future developments of therapy for asthma in children Source: Eur Respir Mon 2012; 56: 224-234 Year: 2012 Recommendations of new therapies for severe asthma and the future Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma Year: 2013 Emerging biologic approaches for the treatment of difficult to control asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 Mechanisms of COPD exacerbations - molecular perspectives and pathophysiology Source: ERS Satellites 2021 Year: 2021 Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD Source: Eur Respir J 2013; 42: 891-892 Year: 2013 Aetiology of exacerbations of asthma and COPD: new viruses, new mechanisms Source: Annual Congress 2010 - Severe exacerbations in asthma and COPD: new causes, mechanisms and models of care Year: 2010 Photobiomodulation acting as an immunotherapeutic strategy for chronic obstructive diseases such as asthma and COPD Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020 Do we need new therapies for noneosinophilic asthma? Source: Annual Congress 2004 - Noneosinophilic asthma Year: 2004 Challenges in COPD exacerbations and future research and unknowns Source: Annual Congress 2013 –Recommendations from the ERS/ATS Guideline on COPD Exacerbation Prevention Year: 2013 Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Genes, mechanisms and new therapies for asthma Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Dose-FEV1 modeling to support future development of AZD2115, a dual acting bronchodilator for the treatment of COPD Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 COPD exacerbation etiological and therapeutically aspects Source: Eur Respir J 2002; 20: Suppl. 38, 543s Year: 2002